Our functional studies confirm that down‐regulation of Bcl‐xL and Mcl‐1 and up‐regulation of Bim contribute to the antitumour activity of CUDC‐907 against prostate cancer cells. This evidence concerns the gene BCL2L1 and prostate carcinoma.